SRT Therapeutics is a fast-paced, science-driven biopharma company focused on advancing innovative biologics. We are seeking a highly motivated and independent Scientist II to lead protein characterization and antibody developability efforts within our Protein Sciences team. This role is central to our early-stage discovery and development programs, requiring a strategic thinker who can translate complex biophysical data into actionable insights for therapeutic candidate selection.
The successful candidate will serve as a subject matter expert in the analytical and biophysical profiling of diverse therapeutic formats (e.g., mAbs, multispecifics, and ADCs). You will be responsible for hands-on characterization of molecule purity and stability, review of comprehensive developability assessments, troubleshooting complex technical challenges, and driving the analytical strategy to de-risk and accelerate our biologics pipeline.
SRT Therapeutics is a San Diego-based biotech company established in 2024 by the founders of Prometheus Biosciences, Steph Targan, MD (Cedars Sinai), Janine Bilsborough, Ph.D. (Cedars Sinai), the scientific team that discovered Tulisokibart (MK7240) and the role of TL1A in IBD and Scott Glenn and Lauren Otsuki, the drug development team that took Tulisokibart (MK7240) from academia into the clinic. Building on the demonstrated success of the precision medicine approach in IBD with Tulisokibart, SRT Therapeutics will expand this approach by targeting key pathways that not only modulate inflammatory pathways, but also promote tissue healing in IBD. This strategy will move SRT Therapeutics beyond the current empirical treatment model to realize the goal of enhancing both outcomes and the quality of care for our patients.
View company profile →